Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO3AJS)

Drug Name

DG031 Drug Info

Synonyms

Veliflapon; 128253-31-6; Bay-x-1005; Bay X 1005; DG-031; Bayx-1005; Bay X1005; UNII-JXH6X663L0; Bay-X1005; BAY 1005; DG 031; CHEMBL88712; JXH6X663L0; 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; Benzeneacetic acid, alpha-cyclopentyl-4-(2-quinolinylmethoxy)-, (R)-; C23H23NO3; BAY-X 1005; (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid; Veliflapon [USAN:INN]; Velifapon; Veliflapon (USAN/INN); AC1L3X6M; MLS006010705; Benzeneacetic acid, a-cyclopentyl-4-(2-quinolinylmethoxy)-,(aR)-; GTPL5148

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Discontinued in Phase 3	[1]

Cross-matching ID

PubChem CID: 123723
CAS Number: CAS 128253-31-6
TTD Drug ID: DMO3AJS

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Arachidonate 5-lipoxygenase activating protein (FLAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK2190915	DM89AV2	Asthma	CA23	Discontinued in Phase 2	[3]
AM103	DMAQNBW	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[4]
GSK2190914	DMHZQ0T	Asthma	CA23	Discontinued in Phase 2	[5]
AZD4769	DMA3OWI	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[6]
A-93178	DM1KBAY	Allergy	4A80-4A85	Terminated	[7]
L-671,480	DMP4QCJ	Discovery agent	N.A.	Investigative	[8]
L-689,037	DMCH3ZK	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 5-lipoxygenase activating protein (FLAP)	TTDMBF5	AL5AP_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5148).
2	BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4	AM103 Experimental Treatment for Respiratory Diseases. Amira Pharmaceuticals/GSK. 2009.
5	FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Investig Drugs. 2009 Nov;10(11):1163-72.
6	5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol Pharmacol. 1992 Feb;41(2):267-72.
7	Characterization of A-93178, an iminoxy-quinoline inhibitor of leukotriene biosynthesis. Adv Exp Med Biol. 1997;433:91-4.
8	5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol. 1991 Jul;40(1):22-7.